Division of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama 35233, USA.
Clin J Am Soc Nephrol. 2010 Aug;5(8):1458-62. doi: 10.2215/CJN.01230210. Epub 2010 May 24.
Concentrated heparin solutions are instilled into the catheter lumens after each hemodialysis session to prevent catheter thrombosis. The heparin lock concentration at many centers has been decreased recently to reduce the risk of systemic bleeding and contain costs. However, the effect of this change on catheter patency is unknown. We compared catheter patency between two heparin lock solutions: 1000 versus 5000 units/ml.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: With use of a prospective, computerized, vascular access database, 105 patients with newly placed tunneled hemodialysis catheters, including 58 patients receiving a 5000 units/ml heparin lock and 47 patients receiving a 1000 units/ml heparin lock, were retrospectively identified. The primary endpoint was cumulative catheter patency and the secondary endpoint was frequency of thrombolytic instillation.
Cumulative catheter survival was similar in the two groups, being 71% versus 73% at 120 days in the low- and high-concentration heparin lock groups (hazard ratio of catheter failure, 0.97; 95% confidence interval, 0.45 to 2.09; P = 0.95). The frequency of tissue plasminogen activator instillation was significantly greater in the low-concentration heparin group (hazard ratio, 2.18; 95% CI, 1.26 to 3.86; P = 0.005). No major bleeding complications were observed in either treatment group. The overall drug cost for maintaining catheter patency was 23% lower with the low-concentration heparin lock ($1418 versus $1917) to maintain catheter patency for 1000 days.
Low-concentration heparin lock solutions do not decrease cumulative dialysis catheter patency, but require a twofold increase in thrombolytic instillation to maintain long-term patency.
每次血液透析后,将浓缩肝素溶液注入导管腔以预防导管血栓形成。最近,许多中心的肝素锁浓度已降低,以降低全身性出血风险并控制成本。但是,这种变化对导管通畅性的影响尚不清楚。我们比较了两种肝素锁溶液(1000 单位/毫升和 5000 单位/毫升)的导管通畅性。
设计、设置、参与者和测量:使用前瞻性计算机化血管通路数据库,回顾性地确定了 105 例新放置的隧道式血液透析导管患者,包括 58 例接受 5000 单位/毫升肝素锁治疗的患者和 47 例接受 1000 单位/毫升肝素锁治疗的患者。主要终点是累积导管通畅率,次要终点是溶栓灌注的频率。
两组的累积导管生存率相似,低浓度肝素锁组和高浓度肝素锁组在 120 天时分别为 71%和 73%(导管失败的风险比为 0.97;95%置信区间,0.45 至 2.09;P = 0.95)。低浓度肝素组溶栓灌注的频率明显更高(风险比为 2.18;95%置信区间,1.26 至 3.86;P = 0.005)。两组均未观察到重大出血并发症。低浓度肝素锁维持导管通畅 1000 天的药物总成本比高浓度肝素锁降低 23%(1418 美元对 1917 美元)。
低浓度肝素锁溶液不会降低累积透析导管通畅率,但需要增加两倍的溶栓灌注才能维持长期通畅性。